title: Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.
authors.affiliation: Department of Neurology, Yale University School of Medicine, , New Haven, Connecticut, USA.
authors.forename: Benison
authors.initials: B
authors.lastname: Keung
authors.forename: Kimberly R
authors.initials: KR
authors.lastname: Robeson
authors.forename: Daniel B
authors.initials: DB
authors.lastname: DiCapua
authors.forename: Jennifer B
authors.initials: JB
authors.lastname: Rosen
authors.forename: Kevin C
authors.initials: KC
authors.lastname: O'Connor
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Goldstein
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Nowak
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use*; D001323:Autoantibodies / Q000276:immunology*; D004351:Drug Resistance / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000276:immunology*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000276:immunology*; D011950:Receptors, Cholinergic / Q000276:immunology*; D012189:Retrospective Studies; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D011950:Receptors, Cholinergic; D000069283:Rituximab; C095714:MUSK protein, human; D020794:Receptor Protein-Tyrosine Kinases
keywords: Myasthenia; Neuroimmunology; Neuromuscular